NEW YORK, July 2 (UPI) -- Sanofi-Aventis is withdrawing its application for U.S. approval of its potential obesity drug on reports that it causes suicidal thoughts.
According to a report in the Wall Street Journal, the company decided to pre-empt rejection of the new drug application for rimonabant by the Food and Drug Administration.
Advertisement
The FDA was set to make a decision on the application by July, the report said. However, the WSJ added, Sanofi-Aventis may consider resubmitting the application to gain approval of the drug as a treatment for diabetes.